GOPView iRVPlus delivers real-time, low- dose image enhancement
BALTIMORE, Maryland and BOSTON, Mass. and STOCKHOLM, Sweden – January 25, 2010 – ContextVision, software imaging partner for the most recognized medical imaging manufacturers worldwide, today announced the results of an animal study conducted at the Johns Hopkins University School of Medicine. Designed to test the performance of ContextVision’s real-time interventional radiology product, researchers concluded that images post-processed using GOPView iRVPlus with a low dose (up to 50 percent less than normal) produced image quality comparable to unprocessed high-dose images.
In this qualitative study, radiologists compared unprocessed, high-dose images with post-processed images collected using a low dose (40 to 50 percent less than the high dose). Each image was reviewed for five parameters: overall diagnostic acceptability, visibility of large vessels, visibility of small vessels, visibility of spinal structures, and presence of artifacts. In all cases, the low dose images quality exceeded that of the unprocessed high-dose images.
Dr. Eleni Liapi, Department of Radiology and Radiological Science, Division of Interventional Radiology, at the Johns Hopkins University School of Medicine presented the study results at RSNA 2009. Dr. Liapi worked with the team to establish the following study methods:
- Standard dose: 160–200mA, 80Kv
- Low dose: 63–125mA, 80Kv
- Female porcine
- Dose measured using a real-time dosimeter
Dr. Liapi commented, “The use of real-time adaptive filters, like GOPView iRVPlus , in all low-dose angiograms led to significant improvement in diagnostic acceptability. The low-dose images were comparable to those derived with a full dose in terms of the visibility of large and small vessels and spinal structures”
“These results reinforce the quality and capabilities of GOPView iRVPlus ,” said Donald Barry, Product General Manager, X-ray Division. “Both advanced image enhancement capabilities and dose reduction top ContextVision’s priority list across all modalities. A long-term ContextVision focus, our customers are increasingly calling for tools that can maximize image quality and reduce dose for both patients and clinicians.”
About GOPView iRVPlus
Released at RSNA 2008 and shipped to customers beginning in 2009, GOPView iRVPlus enables image enhancement at a level never before achieved in interventional radiology. It enables a dose reduction of up to one half, which minimizes both patient and medical staff exposure during a procedure, without any compromise in image quality or diagnostic value.
GOPView iRVPlus relies on a continuous adaptive filtration method to analyze every pixel in an image, giving every structure in the image the same level of analysis. This rotationally invariant process eliminates the risk of critical information being overlooked during a procedure, leading to higher clinical value.
Like all ContextVision products, GOPView iRVPlus uses a proprietary algorithm, GOP, which simultaneously enhances all structures and reduces noise. The image enhancement ensures that more details can be seen while introducing less blur. Additionally, an extensive and growing library of adaptive filters fine-tunes images.
ContextVision is the leading independent developer in medical imaging enhancement, analysis and processing technologies, serving leading OEMs and distributors for more than 25 years. ContextVision’s patented GOP algorithm allows unprecedented image quality to be achieved by simultaneously enhancing fine structure while reducing noise and speckle across MRI, X-Ray, Ultrasound and CT image data.
ContextVision’s technology enables the company’s customers to provide superior digital imaging quality for hospitals and clinicians. Such solutions promise more rapid and accurate diagnoses, reduced operator eye fatigue, and ultimately, a greater return-on-investment for medical imaging users. ContextVision’s embedded imaging software is relied upon daily by thousands of users around the globe. For more information, please visit www.contextvision.com.